151099-27-3 Usage
Chemical class
Naphthyridine derivative
Functional groups
Hydroxyl (-OH), Ethoxy (-OCH2CH3), and Dimethyl (-CH3) groups
Structural features
The naphthyridine ring system consists of a fused six-membered nitrogen-containing ring and a five-membered ring
Positional substituents
The hydroxyl group is at the 4-position, the ethoxy group is at the 6-position, and the dimethyl groups are at the 2and 7-positions
Potential applications
Pharmaceutical (due to unique structure and properties)
Research status
Further research and testing required to understand potential uses and effects
Registry number
9CI (Chemical Abstracts Service Registry Number)
Solubility
Not specified in the provided material, but generally, similar compounds may be soluble in organic solvents like methanol, ethanol, or dimethyl sulfoxide (DMSO)
Stability
Not specified in the provided material, but generally, similar compounds may be stable under normal temperature and pressure conditions, but sensitive to light, heat, or moisture
Safety precautions
Not specified in the provided material, but generally, similar compounds may require proper handling, storage, and disposal to minimize health and environmental risks
Please note that some properties, such as solubility, stability, and safety precautions, are not explicitly mentioned in the provided material. The information given is based on general knowledge of similar compounds and should be verified through further research and testing.
Check Digit Verification of cas no
The CAS Registry Mumber 151099-27-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,1,0,9 and 9 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 151099-27:
(8*1)+(7*5)+(6*1)+(5*0)+(4*9)+(3*9)+(2*2)+(1*7)=123
123 % 10 = 3
So 151099-27-3 is a valid CAS Registry Number.
151099-27-3Relevant articles and documents
Amino naphthyridine compounds as anti-rhoumatic agents
-
, (2008/06/13)
This invention relates to compounds of formula I and pharmaceutically acceptable salts thereof STR1 in which R1 represents hydrogen, alkyl, hydroxy, carboxyalkenyl, alkoxycarbonyalkenyl, hydroxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, halogenated alkyl, carboxy alkoxycarbonyl or alkanoylamino; R2 represents hydrogen, halo, alkoxy, hydroxy, alkanoyloxy, or phenoxy; R3 represents hydrogen or alkyl; R4 represents hydrogen, halo, alkoxycarbonyl, a benzyloxycarbonyl, alkanoyl, benzoyl, carbamoyl, alkyl, carboxy, hydroxyalkyl or alkylthio; R5 represents hydrogen or alkyl; R6 represents hydrogen, alkyl [optionally substituted by one or more of the following: hydroxy, halo or an amino group of formula --NR12 R13 ], a C3-12 alicyclic hydrocarbon group, phenyl, (cycloalkyl)alkyl or benzyl; R7 represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl, carboxy, or alkoxy; R8 represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl or alkoxy; and R9 represents hydrogen or alkyl; which are antirheumatic agents. Compositions containing these compounds and processes to make them are also disclosed.
